Coming Soon

Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for Relapsed/Refractory MM

The purpose of this study is to see at what doses of etentamig combined with Iberdomide is better tolerated and safe for patients with relapsed/refractory multiple myeloma.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Eben Lichtman
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Blood Conditions
Cancer (Multiple Myeloma)

IRB Number

25-2031

ClinicalTrials.gov

NCT06896916

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.